Regeneron keeps up its co-stimulatory crusade
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
No SOS for Bayer's SOS1
The group goes after a KRAS-related target on which Boehringer recently gave up.
The month ahead: November’s upcoming events
Conferences ramp up, and ASH abstracts near.
European radiopharmaceuticals head for the clinic
First-in-human study starts include radioligands from Akiram and Philogen.
Here comes another PD-1/VEGF bispecific
OncoC4’s AI-081 features among the industry’s latest first-in-human trial initiations.
